Inozyme Pharma/$INZY
About Inozyme Pharma
Ticker
Industry
Employees
Inozyme Pharma Metrics
$110M
-
-$1.55
1.54
-
Price and volume
Market cap
$110M
Beta
1.54
52-week high
$7.80
52-week low
$1.61
Average daily volume
816K
Financial strength
Current ratio
7.683
Quick ratio
7.174
Long term debt to equity
51.009
Total debt to equity
56.52
Interest coverage (TTM)
-18.40%
Management effectiveness
Return on assets (TTM)
-35.69%
Return on equity (TTM)
-79.42%
Valuation
Price to book
1.33
Price to tangible book (TTM)
1.33
Price to free cash flow (TTM)
-1.171
Growth
Earnings per share change (TTM)
7.65%
3-year earnings per share growth (CAGR)
-9.38%
What the Analysts think about Inozyme Pharma
Analyst Ratings
Inozyme Pharma Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
Inozyme Pharma Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
Inozyme Pharma News
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma to Present at Upcoming Investor Conferences
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
FAQs
What’s the current market cap for Inozyme Pharma stock?
What is the P/E ratio for Inozyme Pharma stock?
Does Inozyme Pharma stock pay dividends?
No, Inozyme Pharma (INZY) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Inozyme Pharma dividend payment date?
Inozyme Pharma (INZY) stock does not pay dividends to its shareholders.
What is the beta indicator for Inozyme Pharma?
Inozyme Pharma (INZY) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.